Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants

(2017) Federico Martinón-Torres et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study

(2017) Cheryl Cohen et al.   Lancet Global Health

Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study

(2017) Camelia Savulescu et al.   Lancet Respiratory Medicine

Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study

(2016) Marcela Guevara et al.   Eurosurveillance

Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals

(2016) Li Liu et al.   LANCET

Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan

(2016) Wei-Ju Su et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage

(2016) Fernando Moraga-Llop et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012–2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes

(2016) Andreia N. Horácio et al.   Frontiers in Microbiology

Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study

(2016) Matthew R Moore et al.   Lancet Respiratory Medicine

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

(2016) Mark van der Linden et al.   PLoS One

Pneumococcal serotype evolution in Western Europe

(2015) Myint Tin Tin Htar et al.   BMC INFECTIOUS DISEASES

Pneumococcal Capsules and Their Types: Past, Present, and Future

(2015) K. Aaron Geno et al.   CLINICAL MICROBIOLOGY REVIEWS

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada

(2015) Geneviève Deceuninck et al.   VACCINE

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany

(2015) Mark van der Linden et al.   PLoS One

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants

(2015) Alienke J. Wijmenga-Monsuur et al.   PLoS One

Estimation of the invasive disease potential of Streptococcus pneumoniae in children by the use of direct capsular typing in clinical specimens

(2014) E. del Amo et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

(2013) Walter H.B. Demczuk et al.   CANADIAN JOURNAL OF MICROBIOLOGY

Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

(2013) Ron Dagan et al.   CLINICAL INFECTIOUS DISEASES

Parapneumonic Pleural Effusions Caused by Streptococcus pneumoniae Serotype 3 in Children Immunized with 13-Valent Conjugated Pneumococcal Vaccine

(2013) Charalampos Antachopoulos et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Rapid and Easy Identification of Capsular Serotypes of Streptococcus pneumoniae by Use of Fragment Analysis by Automated Fluorescence-Based Capillary Electrophoresis

(2012) L. Selva et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Pneumococcal vaccines WHO position paper – 2012 – Recommendations

(2012) WHO Publication   VACCINE

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

(2011) Otto G. Vanderkooi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study

(2011) Angela Domínguez et al.   VACCINE

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

(2010) K. A. Bryant et al.   PEDIATRICS

Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs. 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine

(2009) L. Salleras et al.   CLINICAL MICROBIOLOGY AND INFECTION

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada

(2009) I. Feavers et al.   VACCINE

Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR

(2008) D. Tarragó et al.   CLINICAL MICROBIOLOGY AND INFECTION